Abstract: Adjustments for lead and length time bias has been used when examining apparent survival advantages from screening procedures. However, these estimates depend on several assumptions and are modeled from malignancies that are fairly common and large cohorts are available. In smaller retrospective cohorts, adjustments themselves may be based on estimates that may not be biological nor statistically accurate, which can lead to divergent results as has been found in several recent studies of screening in Barrett's esophagus. Only a prospective randomized controlled trial can really determine the benefi t though this may not feasible.
To make an impact on the mortality for esophageal adenocarcinoma, several societies have recommended that selective screening be implemented ( 1 ) . Th e primary motivation for this has been the unfortunate situation that over 90% of those that develop this malignancy never had a previous diagnosis of Barrett's esophagus and present with obstructive symptoms ( 2, 3 ) . Th e mortality rates for symptomatic esophageal adenocarcinoma are among the top fi ve cancers in the United States despite the advancements in neoadjuvant therapy and esophagectomy ( 4 ) . Th e recommendation for screening is more born from frustration than evidence that screening will be successful in decreasing mortality.
It is a tenet of cancer screening and surveillance that earlier detection will lead to discovery of earlier stage disease that in turn can lead to successful treatment and improved survival. However, in several neoplastic processes, this has not been found to be the case and earlier diagnosis has not really changed the ultimate course of the disease. Th e best study design by which improved outcomes from screening can be shown is by a population-based prospective randomized trial comparing a screening procedure to no screening and examining overall and disease-specifi c mortality as the end points. Unfortunately, this study design is the least oft en performed, given the large number of patients who would have to be enrolled and the long time periods needed for observation to demonstrate a survival benefi t. In this issue the study by Tramantano et al. ( 5 ) , the investigators examined retrospective data and utilized outcomes from Medicare databases for follow-up that is a much more feasible study methodology. Th ey examined 4,978 Medicare patients in the Surveillance, Epidemiology, End Results (SEER) database, to determine the benefi t of detecting the premalignant condition Barrett's esophagus in those that were older than 65 years of age and determined if there was an eff ect on cancer stage and mortality. Th ey found that there was a signifi cant improvement in cancer stage if Barrett's esophagus was detected prior to the diagnosis of cancer. However, when the investigators adjusted their apparent survival benefi ts for both lead and length time bias, there was no longer a survival advantage. Th is is consistent with prior publications that have found that endoscopy prior to detection of esophageal adenocarcinoma did not seem to have an eff ect on outcomes ( 6 ) . A Cochrane review on the benefi ts of screening for esophageal cancer highlighted the need for randomized controlled trials as existing retrospective cohort studies found benefi ts that could be explained by lead and length time bias ( 7 ) . However, another recent large study of 29,536 veterans and 424 esophageal adenocarcinomas found a mean survival benefi t of almost a year and signifi cant improved overall survival rates even when adjusting for bias ( 8 ) .
It is diffi cult to understand the diff erences in conclusions, given the large patient populations studied and the careful methods used by experienced investigators. First, it is important to realize that the populations selected are primarily of convenience since esophageal cancer is not common necessitating very large cohorts to be assembled with lengthy follow-up periods. However, the diffi culty with using these large databases is the need to reduce confounding by imputing a mathematical model to Atlas publication on the genetic composition of esophageal adenocarcinoma of the tubular esophagus assumed to be primarily related to Barrett's esophagus, no distinct subset could be found as distinguished by methylation profi les, expression profi les, copynumber abnormalities, or genetic mutations that raises the issue of the two diff erent populations of cancer being too simplistic ( 10 ) . Th ere does not really seem to be two distinct populations with diff erent sojourn times if esophageal cancers are so genetically diverse. In breast cancer, it has been found that those with estrogen receptor positivity do constitute a more indolent form of the cancer with prolonged survival times that makes the adjustment more plausible in this malignancy.
Th ese issues are typically why it is necessary to perform the randomized control trial to really be able to be certain that screening can actually aff ect outcomes. In lieu of the defi nitive studies, it is necessary to estimate as best as we can the potential bias, but in diseases with relatively small number of events, it is not surprising that diff erent groups arrive at diff erent estimates of length and lead time bias that confi rm the benefi ts in one study but completely eliminate them in another.
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Guarantor of the article : Kenneth K. Wang, MD. Specifi c author contributions : All authors contributed equally to writing and editing the article. Financial support : K.K.W. has received funding from the National Cancer Institute through grants U54 CA163004-06 and U01 CA182940-04. Potential competing interests : None. account for bias from lead and length time. Th e two are related since those more indolent tumors that are detected more oft en by screening contribute to lead time bias by being more available for detection by periodic surveillance. Th ese less aggressive tumors also contribute to length time bias by tending to have longer survival. Th e adjustment used by the investigators was fi rst described by Duff y et al. ( 9 ) and was based on screening for breast cancer using mammography. Th ese investigators created models to compensate lead time bias that is related to the apparent increase in survival that occurs when a disease is diagnosed earlier, but the clinical course is actually unchanged. Th is is carried out by estimating the size of tumors that are detected on surveillance and the size of tumors found in patients not in surveillance, and then comparing their subsequent survival. Th ese calculations are based on estimations of sojourn time that is defi ned as being the period a tumor is detectable by screening but asymptomatic. Th e sojourn time is assumed to follow an exponential distribution. In the calculations used to develop lead time bias adjustment, the authors used data from other large breast cancer screening studies to estimate the sojourn time. To correct for length time bias, probabilities were estimated for a two tumor type model; one tumor type being a rapidly growing tumor and another being signifi cantly slower with each having diff erent probabilities to be screen-detected. Th e probabilities were then examined using plausible values that were varied using sensitivity analysis. Using these calculations, it was found that to assume length time bias totally accounted for diff erences in screening detected cancer survival, the group with the slower tumors would have to consist of at least 30% of total tumors and be fi ve times more likely to be detected by surveillance.
Th ere are several diff erences in the population and assumptions used in this study to explain the lack of benefi t that is found. Since the authors of this Barrett's esophagus study confi ned the sample to those over 65 years of age due to the need to use the Medicare database, it would appear that both length and lead time bias adjustments would need to be shortened since the initial age of detection could only begin at age 65. It needs to be kept in mind that screening, when suggested by most gastroenterology societies, would begin by age 50. Th is raises the possibility that the fast growing cancer type that is more aggressive may no longer be available for screening at this age as this may have already produced mortality.
In addition, these adjustments are statistically based and the larger the patient population used, the more accurately a probability can be calculated. Esophageal adenocarcinoma is much less common than breast cancer. Th e breast cancer example used to estimate lead and length time bias had 15,862 breast cancers, which is over three times the cohort in the SEER database of esophageal cancer used in this study. Th ere is also a question of biological plausibility for the assumption of two populations of cancers used to adjust for bias. In the recent Th e Cancer Genome
